Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$39.16 USD

39.16
2,512,037

+0.26 (0.67%)

Updated Jul 12, 2024 03:59 PM ET

Pre-Market: $39.05 -0.11 (-0.28%) 9:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK (GSK) Stock Moves -1.04%: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, GSK (GSK) stood at $36.29, denoting a -1.04% change from the preceding trading day.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

GSK (GSK) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $36.67, marking a +0.25% move from the previous day.

Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why

by Zacks Equity Research

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

Why GSK (GSK) Outpaced the Stock Market Today

by Zacks Equity Research

In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

by Zacks Equity Research

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

by Zacks Equity Research

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

GSK (GSK) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $35.89 in the latest trading session, marking a -0.55% move from the prior day.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $36.09 in the latest trading session, marking a -0.44% move from the prior day.

GSK (GSK) Stock Moves -1.14%: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $37.28, moving -1.14% from the previous trading session.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $37.71, marking a +0.75% move from the previous day.

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

by Zacks Equity Research

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down

by Zacks Equity Research

Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $37.48, moving +0.35% from the previous trading session.

Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

by Zacks Equity Research

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia

by Zacks Equity Research

GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

by Zacks Equity Research

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $36.76, marking a -0.27% move from the previous day.

AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo

by Zacks Equity Research

Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.

GSK (GSK) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $34.64 in the latest trading session, marking a +0.67% move from the prior day.